Unlocked, right on the stroke of 5!
Data looks good - TI delivered via the GEN 2 device shows the same bioavailability as the Medtone device.
Medtone:
20-25%
http://www.unboundmedicine.com/evidence/ub/citation/19476477/Pharmacokinetics_and_linear_exposure_of_AFRESA_compared_with_the_subcutaneous_injection_of_regular_human_insulin_
Gen 2:
24%
http://app.core-apps.com/tristar_ada13/abstract/9b942b88cb23351f1c62fdf8084f9f61
Which to me means that the device comparison should be good?
Only concern were hypoglycemic events:
The most frequent adverse event was mild asymptomatic hypoglycemia reported for 85% of subjects after TI dosing and 12.5% following sc insulin which was classified as related to study procedure (ie inability of glucose infusion to respond at a rate to maintain euglycemia post-dosing).
Liane / Anyone:
Can you weigh in on the bioavailability / difference in hypoglycemic events seen?
